ProCE Banner Activity

Recent Developments in Testing for and Targeting HER2, HER3, and TROP2 in Patients With Advanced Breast, GI, and Other Solid Cancers

Clinical Thought
What is new in testing for HER2 in breast cancer and beyond? How might newly approved and emerging therapies targeting HER2, HER3, and TROP2 affect your practice? Here’s my take.

Released: July 23, 2020

Expiration: July 22, 2021

Share

Faculty

Mark D. Pegram

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Program Director Disclosure

Program Director

Mark D. Pegram, MD

Leonard M. Miller School of Medicine
University of Miami
Miami, Florida

Mark D. Pegram, MD, has disclosed that he has received consulting fees from AstraZeneca, Daiichi Sankyo, Roche/Genentech, and Seattle Genetics.